Acute PAncreatitis and Home Care vs. Hospital Admission Study (PADI_2)
Primary Purpose
Acute Pancreatitis, Home Care
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Outpatient
Medical home care
Hospitalization
Sponsored by
About this trial
This is an interventional treatment trial for Acute Pancreatitis focused on measuring Pancreatitis
Eligibility Criteria
Inclusion Criteria:
- Diagnosed of AP by at least two of these three criteria: compatible abdominal pain, amylase or lipase level superior in three-fold respective laboratory baseline levels, and suitable findings in imaging techniques (CT, ultrasound or MRI).
- age > 18 years, sign consent form.
Exclusion Criteria:
- pregnant o breastfeeding women.
- abdominal pain lasting >96 horas before admission.
- the possibility of poor oral intake for reasons other than AP.
- Pancreatic neoplasm, endoscopic retrograde cholangiopancreatography or trauma etiology, biliar obstruction.
- Chronic pancreatitis.
- ASA ≥3.
- Randomization lesser the 24 hours after randomization.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
Outpatient
Medical home care
Hospitalization
Arm Description
The Mild AP patient is discharged and contacted daily for 4 consecutive days by the study investigators in each center.
The mild AP patient is discharged and contacted daily for 4 consecutive days by the medical home care department in each center.
The mild AP patient is hospitalized
Outcomes
Primary Outcome Measures
The treatment failure rate
Treatment failure is defined as persistence, increase or recurrence of abdominal pain, and or intolerance diet, hospital admission, and mortality
Secondary Outcome Measures
Relapse of abdominal pain
Pain Scale: 0=No pain, 1=Very mild, 2=Discomforting, 3=Tolerable, 4=Distressing, 5=Distressing, 6=Intense pain, 7=Very intense pain, 8=Horrible pain, 9=Excruciating, 10=Unimaginable pain
Diet tolerance
Patient can eat at least 50% of the meals
Systemic Inflammatory Response Syndrome (SIRS) Score
SIRS is a simple clinical score, ranging from 0-4, that utilizes objective, routine clinical parameters (body temperature, heart rate, respiratory rate or arterial carbon dioxide tension and white blood count) that directly reflect the underlying inflammatory response. A lower change in SIRS score (negative number) indicates a better outcome (less inflammation).
Number of Participants who Development of Organ Failure
Including respiratory, renal and cardiovascular failures defined as modified Marshal score of equal and greater than 2. The minimum and maximum values in the modified Marshal score for each organ failure range from 0 to 4 with a higher value representing worse outcomes.
Mortality
Enrolled subjects that died. A death indicates a worse outcome.
Hospital admission
The AP patient needs hospital admission due to treatment failure
Satisfaction medical / hospital care
patient satisfaction is asessed comparing management with and without admittance to the hospital. Will be assessed Patient satisfaction feedback (PSF). Scale: Strongly agree, Agree, Not sure, Disagree, Strongly disagree.
Health costs
The costs in euros caused by diagnosis, treatment, stay in the emergency room, complications and follow-up
Full Information
NCT ID
NCT05360797
First Posted
March 26, 2022
Last Updated
April 29, 2022
Sponsor
Elena Ramírez-Maldonado
Collaborators
Hospital Clinic of Barcelona, Consorci Sanitari del Maresme
1. Study Identification
Unique Protocol Identification Number
NCT05360797
Brief Title
Acute PAncreatitis and Home Care vs. Hospital Admission Study
Acronym
PADI_2
Official Title
Randomized Multicenter Prospective Clinical Trial to Compare the Effectiveness of Home Care vs Hospital Admission in Patients With Acute Pancreatitis
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 1, 2022 (Anticipated)
Primary Completion Date
July 1, 2022 (Anticipated)
Study Completion Date
July 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Elena Ramírez-Maldonado
Collaborators
Hospital Clinic of Barcelona, Consorci Sanitari del Maresme
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Acute pancreatitis (AP) is one of the most common reason for hospitalization among gastrointestinal diseases in U.S.. The costs caused by severe AP are higher than mild AP. Nevertheless, approximately 70% of hospital admissions for AP are mild cases, if health cost saving is to be realized, it would be by lowering the cost of managing patients with mild AP without affecting patient's safety and satisfaction.
With the PADI-1 study, where it was possible to confirm the benefits of an early diet, the rapid recovery of patients with mild AP and the reduction of hospital costs, now a new scope is to be given in the treatment of patients with this pathology.
Considering the application of predictive factors of AP severity, and being sure of diagnosing mild AP, a study of home care versus hospitalization for patients with mild AP is proposed. Based on the hypothesis that outpatient care of mild AP patients would be as sage and affective as hospitalization, the aim this study is to campare the results of 3 different strategies of treatment of patients with AP mild. Additionally, satisfaction patient and costs will be analyzed.
Detailed Description
This is prospective, randomized, controlled, multicentre trial.
OBJECTIVES
Primary objective Compare the results of 3 different strategies for the management of patients with mild acute pancreatitis (AP) and to analyze differences in satisfaction patients and economic costs.
METHODS
Patients with mild AP will be randomly in three groups: group A: outpatient treatment, group B: medical home care and group C: hospitalization.
The primary and several secondary endpoints will be obtained:
Treatment failure rate (the primary endpoint).
Serum amylase, lipase, electrolytes, BUN (blood urea nitrogen), creatinine, liver function tests, and full blood count at hospital admission, 24 hours and 72 hours.
Relapse pain.
Diet intolerance.
Systemic complications including hemodynamic instability, renal failure, intensive care admission, surgery, radiological and endoscopic procedures.
Pain and Analgesic requirement.
Local complications including pancreatic necrosis, abscess, pseudocyst.
Health costs
Patient satisfaction
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Pancreatitis, Home Care
Keywords
Pancreatitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Ramdomized
Masking
None (Open Label)
Allocation
Randomized
Enrollment
225 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Outpatient
Arm Type
Experimental
Arm Description
The Mild AP patient is discharged and contacted daily for 4 consecutive days by the study investigators in each center.
Arm Title
Medical home care
Arm Type
Experimental
Arm Description
The mild AP patient is discharged and contacted daily for 4 consecutive days by the medical home care department in each center.
Arm Title
Hospitalization
Arm Type
Active Comparator
Arm Description
The mild AP patient is hospitalized
Intervention Type
Other
Intervention Name(s)
Outpatient
Intervention Description
After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the study investigators in each center.
Intervention Type
Other
Intervention Name(s)
Medical home care
Intervention Description
After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the medical home care department in each center.
Intervention Type
Other
Intervention Name(s)
Hospitalization
Intervention Description
After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is hospitalized with usual treatment (PADI_1) in each center.
Primary Outcome Measure Information:
Title
The treatment failure rate
Description
Treatment failure is defined as persistence, increase or recurrence of abdominal pain, and or intolerance diet, hospital admission, and mortality
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Relapse of abdominal pain
Description
Pain Scale: 0=No pain, 1=Very mild, 2=Discomforting, 3=Tolerable, 4=Distressing, 5=Distressing, 6=Intense pain, 7=Very intense pain, 8=Horrible pain, 9=Excruciating, 10=Unimaginable pain
Time Frame
30 days
Title
Diet tolerance
Description
Patient can eat at least 50% of the meals
Time Frame
30 days
Title
Systemic Inflammatory Response Syndrome (SIRS) Score
Description
SIRS is a simple clinical score, ranging from 0-4, that utilizes objective, routine clinical parameters (body temperature, heart rate, respiratory rate or arterial carbon dioxide tension and white blood count) that directly reflect the underlying inflammatory response. A lower change in SIRS score (negative number) indicates a better outcome (less inflammation).
Time Frame
4 days
Title
Number of Participants who Development of Organ Failure
Description
Including respiratory, renal and cardiovascular failures defined as modified Marshal score of equal and greater than 2. The minimum and maximum values in the modified Marshal score for each organ failure range from 0 to 4 with a higher value representing worse outcomes.
Time Frame
4 days
Title
Mortality
Description
Enrolled subjects that died. A death indicates a worse outcome.
Time Frame
30 days
Title
Hospital admission
Description
The AP patient needs hospital admission due to treatment failure
Time Frame
30 days
Title
Satisfaction medical / hospital care
Description
patient satisfaction is asessed comparing management with and without admittance to the hospital. Will be assessed Patient satisfaction feedback (PSF). Scale: Strongly agree, Agree, Not sure, Disagree, Strongly disagree.
Time Frame
30 days
Title
Health costs
Description
The costs in euros caused by diagnosis, treatment, stay in the emergency room, complications and follow-up
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed of AP by at least two of these three criteria: compatible abdominal pain, amylase or lipase level superior in three-fold respective laboratory baseline levels, and suitable findings in imaging techniques (CT, ultrasound or MRI).
age > 18 years, sign consent form.
Exclusion Criteria:
pregnant o breastfeeding women.
abdominal pain lasting >96 horas before admission.
the possibility of poor oral intake for reasons other than AP.
Pancreatic neoplasm, endoscopic retrograde cholangiopancreatography or trauma etiology, biliar obstruction.
Chronic pancreatitis.
ASA ≥3.
Randomization lesser the 24 hours after randomization.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elena Ramírez-Maldonado, PhD
Phone
977295800
Ext
5824
Email
padibarcelona@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elena Ramírez-Maldonado, PhD
Organizational Affiliation
Hospital Universitari Joan XXIII
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rosa Jorba-Martin, PhD
Organizational Affiliation
Hospital Universitari Joan XXIII
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Study protocolo will be shared
IPD Sharing Time Frame
01/08/2022-01/01/2023
IPD Sharing Access Criteria
Pancreatic researchers
Citations:
PubMed Identifier
24854612
Citation
Ince AT, Senturk H, Singh VK, Yildiz K, Danalioglu A, Cinar A, Uysal O, Kocaman O, Baysal B, Gurakar A. A randomized controlled trial of home monitoring versus hospitalization for mild non-alcoholic acute interstitial pancreatitis: a pilot study. Pancreatology. 2014 May-Jun;14(3):174-8. doi: 10.1016/j.pan.2014.02.007. Epub 2014 Mar 14.
Results Reference
result
PubMed Identifier
24054878
Citation
Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013 Jul-Aug;13(4 Suppl 2):e1-15. doi: 10.1016/j.pan.2013.07.063.
Results Reference
result
PubMed Identifier
27007094
Citation
Greenberg JA, Hsu J, Bawazeer M, Marshall J, Friedrich JO, Nathens A, Coburn N, May GR, Pearsall E, McLeod RS. Clinical practice guideline: management of acute pancreatitis. Can J Surg. 2016 Apr;59(2):128-40. doi: 10.1503/cjs.015015.
Results Reference
result
PubMed Identifier
23896955
Citation
Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013 Sep;108(9):1400-15; 1416. doi: 10.1038/ajg.2013.218. Epub 2013 Jul 30. Erratum In: Am J Gastroenterol. 2014 Feb;109(2):302.
Results Reference
result
PubMed Identifier
25973947
Citation
Yokoe M, Takada T, Mayumi T, Yoshida M, Isaji S, Wada K, Itoi T, Sata N, Gabata T, Igarashi H, Kataoka K, Hirota M, Kadoya M, Kitamura N, Kimura Y, Kiriyama S, Shirai K, Hattori T, Takeda K, Takeyama Y, Hirota M, Sekimoto M, Shikata S, Arata S, Hirata K. Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015. J Hepatobiliary Pancreat Sci. 2015 Jun;22(6):405-32. doi: 10.1002/jhbp.259. Epub 2015 May 13.
Results Reference
result
PubMed Identifier
33196485
Citation
Ramirez-Maldonado E, Lopez Gordo S, Pueyo EM, Sanchez-Garcia A, Mayol S, Gonzalez S, Elvira J, Memba R, Fondevila C, Jorba R. Immediate Oral Refeeding in Patients With Mild and Moderate Acute Pancreatitis: A Multicenter, Randomized Controlled Trial (PADI trial). Ann Surg. 2021 Aug 1;274(2):255-263. doi: 10.1097/SLA.0000000000004596.
Results Reference
result
PubMed Identifier
33824864
Citation
Pando E, Alberti P, Mata R, Gomez MJ, Vidal L, Cirera A, Dopazo C, Blanco L, Gomez C, Caralt M, Balsells J, Charco R. Early Changes in Blood Urea Nitrogen (BUN) Can Predict Mortality in Acute Pancreatitis: Comparative Study between BISAP Score, APACHE-II, and Other Laboratory Markers-A Prospective Observational Study. Can J Gastroenterol Hepatol. 2021 Mar 22;2021:6643595. doi: 10.1155/2021/6643595. eCollection 2021.
Results Reference
result
Learn more about this trial
Acute PAncreatitis and Home Care vs. Hospital Admission Study
We'll reach out to this number within 24 hrs